AI assistant
Emergent BioSolutions Inc. — Director's Dealing 2017
Jan 20, 2017
32870_dirs_2017-01-19_d0ef97a6-1d65-410d-b968-f1a1a5562675.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-01-17
Reporting Person: Bailey Sue (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-08-01 | Common Stock | J | 152 | $0.0 | Acquired | 34637 | Direct |
| 2016-08-01 | Common Stock | J | 604 | $0.00 | Acquired | 35241 | Direct |
| 2016-08-01 | Common Stock | J | 577 | $0.00 | Acquired | 35818 | Direct |
| 2017-01-17 | Common Stock | M | 3157 | $10.64 | Acquired | 38975 | Direct |
| 2017-01-17 | Common Stock | S | 3157 | $29.7789 | Disposed | 35818 | Direct |
| 2017-01-17 | Common Stock | M | 3157 | $14.71 | Acquired | 38975 | Direct |
| 2017-01-17 | Common Stock | S | 3157 | $29.7789 | Disposed | 35818 | Direct |
| 2017-01-17 | Common Stock | M | 3157 | $20.08 | Acquired | 38975 | Direct |
| 2017-01-17 | Common Stock | S | 3157 | $29.7789 | Disposed | 35818 | Direct |
| 2017-01-17 | Common Stock | M | 4735 | $13.37 | Acquired | 40553 | Direct |
| 2017-01-17 | Common Stock | S | 4735 | $29.7789 | Disposed | 35818 | Direct |
| 2017-01-17 | Common Stock | M | 3157 | $13.00 | Acquired | 38975 | Direct |
| 2017-01-17 | Common Stock | S | 3157 | $29.7789 | Disposed | 35818 | Direct |
| 2017-01-17 | Common Stock | M | 2061 | $18.64 | Acquired | 37879 | Direct |
| 2017-01-17 | Common Stock | S | 2061 | $29.7789 | Disposed | 35818 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-08-01 | Stock Option (Right to buy) | $10.64 | J | 277 | Acquired | 2019-05-20 | Common Stock (277) | Direct |
| 2017-01-17 | Stock Option (Right to buy) | $10.64 | M | 3157 | Disposed | 2019-05-20 | Common Stock (3157) | Direct |
| 2016-08-01 | Stock Option (Right to buy) | $14.71 | J | 277 | Acquired | 2020-05-19 | Common Stock (277) | Direct |
| 2017-01-17 | Stock Option (Right to buy) | $14.71 | M | 3157 | Disposed | 2020-05-19 | Common Stock (3157) | Direct |
| 2016-08-01 | Stock Option (Right to buy) | $20.08 | J | 416 | Acquired | 2021-05-18 | Common Stock (416) | Direct |
| 2017-01-17 | Stock Option (Right to buy) | $20.08 | M | 3157 | Disposed | 2021-05-18 | Common Stock (3157) | Direct |
| 2016-08-01 | Stock Option (Right to buy) | $13.37 | J | 693 | Acquired | 2019-05-16 | Common Stock (693) | Direct |
| 2017-01-17 | Stock Option (Right to buy) | $13.37 | M | 4735 | Disposed | 2019-05-16 | Common Stock (4735) | Direct |
| 2016-08-01 | Stock Option (Right to buy) | $13.00 | J | 693 | Acquired | 2020-05-22 | Common Stock (693) | Direct |
| 2017-01-17 | Stock Option (Right to buy) | $13.00 | M | 3157 | Disposed | 2020-05-22 | Common Stock (3157) | Direct |
| 2016-08-01 | Stock Option (Right to buy) | $18.64 | J | 905 | Acquired | 2021-05-21 | Common Stock (905) | Direct |
| 2017-01-17 | Stock Option (Right to buy) | $18.64 | M | 2061 | Disposed | 2021-05-21 | Common Stock (2061) | Direct |
Footnotes
F1: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.
F2: In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.
F3: In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.
F4: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey.
F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive.
F6: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
F7: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off.
F8: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.